Trial Profile

A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary)
Indications Coronary artery disease; Hypercholesterolaemia
Focus Adverse reactions
Sponsors Amgen

Most Recent Events

30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
20 Mar 2018 Status changed from active, no longer recruiting to completed.
20 Mar 2018 This trial has been Discontinued in Spain (on 2018-02-28).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com